Kuehn Law Encourages HA, ICVX, PXD, and HARP Investors to Contact Law Firm
19 janv. 2024 13h15 HE
|
KUEHN LAW, PLLC
Kuehn Law investigates HA, ICVX, PXD, HARP mergers, seeks to protect shareholder interests. Shareholders urged to contact the firm.
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – HA, KRTX, EAR, ICVX
09 janv. 2024 17h30 HE
|
Monteverde & Associates PC
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – ICVX, PGTI, KRTX, CSTR
04 janv. 2024 20h00 HE
|
Monteverde & Associates PC
NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
SHAREHOLDER ALERT: Juan Monteverde Encourages the Shareholders of ICVX, EAR, CVLY, IMGN to Take Action
26 déc. 2023 19h19 HE
|
Monteverde & Associates PC
NEW YORK, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
ALERT: Juan Monteverde Encourages the Shareholders of HOLI, EGLE, ICVX to Take Action
13 déc. 2023 20h00 HE
|
Monteverde & Associates PC
NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Icosavax; Is the Deal in the Best Interest of Shareholders?
12 déc. 2023 07h49 HE
|
Johnson Fistel, LLP
Is the Deal in the Best Interest of Shareholders?
Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14 nov. 2023 16h05 HE
|
Icosavax, Inc.
- Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV - - IVX-A12 (RSV+hMPV) Phase 2 topline interim data expected by end of 2023...
Icosavax to Participate in the Jefferies London Healthcare Conference
08 nov. 2023 08h00 HE
|
Icosavax, Inc.
SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference
31 oct. 2023 08h00 HE
|
Icosavax, Inc.
SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
19 sept. 2023 08h00 HE
|
Icosavax, Inc.
SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...